This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 15, 2022.

Further funding secured: Stenocare has prepared to add a further financial instrument at this week's General Meeting on Friday November 18, 2022. The new instrument is a convertible loan facility of up to 11 mDKK, that enables the company to issue loans (convertible bonds) where the lenders have the opportunity to convert to shares at a price that is fixed to 25% above market-price on issue. Stenocare has already received firm commitments of 3,9 mDKK with repayment in January 2024. These commitments are considered sufficient to finance the company until break-even, and the funds are ready to be released to the company following the approval of the instrument at the General Meeting on Friday. For further details regarding the loan model please see the documents for General Meeting November 18, 2022.

On track towards Q4 sales run rate: The Stenocare pharma approach has secured market entry with 11 full spectrum medical cannabis oil products into 5 highly regulated countries. In partnership with local pharma distributors, the company now has access to markets with attractive growth potential in the coming years. On March 10[th] this year, Stenocare issued guidance that it would reach a quarterly sales run rate of 4-5 mDKK by end of 2022, corresponding to an annual sale of 16-20 mDKK or more in 2023. This expectation was founded on Stenocare historic performance during 2018/2019, where sales reached more than 4 mDKK in Q1-2019 with profits of 1,5 mDKK. At that time, Stenocare was in one market (Denmark) with 3 products. The company is currently preparing the first major shipment of products into Norway and the first shipment of CBD-product into Denmark. These deliveries represent combined sales value of 3-4 mDKK and are ready for shipment today with expected arrival by the end of December, pending export permits from the Canadian Health Authorities. This means, that Stenocare is on track to reach the quarterly sales run rate as previously communicated, and that the guidance for 2023 is well within reach.

Operating a lean business to break-even: Stenocare is running a lean business and is able to calibrate the level of investments and costs with the market situation and financial liquidity at any time. On this basis, Stenocare expects to reach break-even by the end of 2023 without raising further capital. However, the Board of Directors and management team is constantly monitoring opportunities to make investments and accelerate the STENOCARE 2.0 strategy to become a leading brand for medical cannabis in Europe.